Drug Development
Therapeutic Pipeline
Membrane protein-targeted therapeutic pipeline. Candidates discovered through our RuCIA platform are advancing into global clinical trials.
RCI001
Target: TRPV1-Rac1 Downstream Modulator
Unlike direct TRPV1 channel antagonists, RCI001 modulates the TRPV1 downstream Rac1/NLRP3 inflammatory cascade — restoring tear film homeostasis and corneal epithelial healing without blocking thermosensation. Differentiated MoA addresses root inflammatory cause, not just symptoms.
Key Details
- •Differentiated MoA: downstream signal modulator (not a direct TRPV1 antagonist)
- •Global development: US FDA Phase 2 + Korea Phase 2 (2026)
- •0.25% topical ophthalmic solution — non-steroidal, well-tolerated
- •Sjögren's syndrome model: tear secretion increase within 1 week
- •Therapeutic onset within 4 weeks (vs 8-12 weeks for steroid alternatives)
- •Overcomes steroid side effects: no IOP elevation, no redness, no burning
- •Avoids thermosensation blockade common to first-gen TRPV1 antagonists
- •TRPV1 active-disease treatment patents granted in Korea, Japan, US
Milestones
RCI001AH
Target: TRPV1-Rac1 Downstream Modulator
Same mechanism of action as RCI001 — modulates the TRPV1 downstream Rac1/NLRP3 inflammatory cascade. Veterinary formulation targeting dry eye in companion animals (dogs/cats).
Key Details
- •Same mechanism of action as RCI001 (TRPV1-Rac1/NLRP3 downstream modulation)
- •Targets dry eye (KCS) in companion animals (dogs/cats)
- •PoC study complete
- •Comparative study vs veterinary cyclosporine conducted
- •Co-development with multinational veterinary pharma, targeting 2030 market entry
Milestones
RCI002
Target: MOR Agonist · Intra-articular Delivery
High-potency MOR agonist for intra-articular delivery — local analgesia with minimized systemic exposure. CRPS Orphan Drug Designation submitted
Key Details
- •Indications: CRPS, OA, diabetic neuropathy, CIPN, fibromyalgia
- •Intra-articular delivery minimizes systemic exposure
- •Single dose: 2+ weeks pain reduction in OA model
- •No body-temperature elevation observed in rodent and marmoset studies
- •FDA Orphan Drug Designation (ODD) for CRPS submitted
Milestones
RCI003
Target: Selective Modulator of Psoriasis Target Proteins
AI drug platform-based selective modulation of psoriasis target proteins — leveraging TRPV1 ion channel expertise
Key Details
- •Syntekabio AI platform (STB) for target protein analysis
- •RudaCure TRPV1 expertise applied to skin disease ion channels
- •Sogang University: compound synthesis & optimization
- •Inje University: candidate compound efficacy evaluation
- •Research period: Apr 2026 – Mar 2028
Milestones
RC0125 AAV
Target: TRPV4 Intracellular Target (AAV Vector)
AAV vector-based gene therapy targeting intracellular TRPV4 — developed as an orphan drug with plans to expand to related diseases
Key Details
- •AAV vector-based gene therapy targeting intracellular TRPV4 channel
- •Proven analgesic efficacy in osteoarthritis (OA) animal models
- •Currently undergoing candidate drug optimization
- •Initial development targets rare orphan disease CMT2C, with plans for expansion to related disorders
Milestones
Talk to us about the pipeline
Stage-by-stage material and investor information are ready. Partnership and licensing enquiries come through the same channel.